Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments
Drug Discoveries & Therapeutics · 2025
DOI: 10.5582/ddt.2025.01044 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Drug Discoveries & Therapeutics, 2025. Verfasst von Toshimasa Shimizu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Naga-saki University Graduate School of Biomedical Scien…. Hauptthemen laut MEDLINE: Infliximab, Arthritis, Rheumatoid, Biosimilar Pharmaceuticals, Antirheumatic Agents. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Naga-saki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
- Department of Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.
- Department of Internal Medicine, Tobata General Hospital, Kitakyushu, Japan.
- Yoshitama Clinic for Rheumatic Diseases, Kagoshima, Japan.
Zitieren
APA
Shimizu, T., Kawashiri, S. Y., Koga, T., Kiya, R., Morita, M., Kuroda, S., Tashiro, S., Sato, S., Yano, H., Asano, T., Saito, K., Yoshitama, T., Ueki, Y., Eiraku, N., Yamada, Y., Okano, T., Ushio, Y., Dobashi, H., Itami, T., …, & Kawakami, A. (2025). Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments. Drug Discoveries & Therapeutics. https://doi.org/10.5582/ddt.2025.01044
Vancouver
Shimizu T, Kawashiri SY, Koga T, Kiya R, Morita M, Kuroda S, et al. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments. Drug Discoveries & Therapeutics. 2025. doi:10.5582/ddt.2025.01044
BibTeX
@article{Shimizu2025,
author = {Shimizu, Toshimasa and Kawashiri, Shin-Ya and Koga, Tomohiro and Kiya, Rieko and Morita, Michiko and Kuroda, Shohei and Tashiro, Shigeki and Sato, Shuntaro and Yano, Hiroshi and Asano, Tomoyuki and Saito, Kazuyoshi and Yoshitama, Tamami and Ueki, Yukitaka and Eiraku, Nobutaka and Yamada, Yutaro and Okano, Tadashi and Ushio, Yusuke and Dobashi, Hiroaki and Itami, Tetsu and Tomita, Daisuke and Nozaki, Yuji and Hosogaya, Naoki and Yamamoto, Hiroshi and Kawakami, Atsushi},
title = {Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments},
journal = {Drug Discoveries & Therapeutics},
year = {2025},
doi = {10.5582/ddt.2025.01044}
}
EUVIMED